Similarly, a prospective Scandinavian study on 546 MASLD patients showed that PNPLA3 GG homozygosity was associated with a higher prevalence of baseline MASH (OR 3.67) and that after a median follow‐up of 40 years, the same genetic profile was associated with a higher rate of severe liver disease (aHR 2.27 compared with the CC wild‐type phenotype). This evidence concerns the gene PNPLA3 and liver disorder.